News
PLX
2.090
+1.95%
0.040
Weekly Report: what happened at PLX last week (0608-0612)?
Weekly Report · 2h ago
Weekly Report: what happened at PLX last week (0601-0605)?
Weekly Report · 06/08 09:37
Weekly Report: what happened at PLX last week (0525-0529)?
Weekly Report · 06/01 09:39
Ram Selvaraju Reiterates Buy on Protalix, Maintains $12 Price Target on Elfabrio Momentum and Pipeline Upside
TipRanks · 05/26 10:35
Weekly Report: what happened at PLX last week (0518-0522)?
Weekly Report · 05/25 09:40
Protalix Highlights Elfabrio Dosing Approvals and Growth Plans
TipRanks · 05/21 11:33
Weekly Report: what happened at PLX last week (0511-0515)?
Weekly Report · 05/18 09:40
Protalix Q1 Call: Milestone-Fueled Profit, Bold Targets
TipRanks · 05/14 00:15
Protalix reaffirms $78M-$83M 2026 revenue outlook following $25M Elfabrio milestone
Seeking Alpha · 05/13 15:52
CORRECTION: Protalix BioTherapeutics Q1 EPS $0.22 Beats $0.06 Estimate, Sales $33.750M Beat $11.468M Estimate
Benzinga · 05/13 13:37
Transcript: Protalix BioTherapeutics Q1 2026 Earnings Conference Call
Benzinga · 05/13 12:19
Earnings Scheduled For May 13, 2026
Benzinga · 05/13 11:11
Protalix BioTherapeutics Q1 EPS $0.05 Misses $0.06 Estimate, Sales $33.750M Beat $11.468M Estimate
Benzinga · 05/13 11:02
Protalix BioTherapeutics give Q1 results
Seeking Alpha · 05/13 10:53
Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results
PR Newswire · 05/13 10:50
Here are the major earnings before the open Wednesday
Seeking Alpha · 05/12 22:00
Protalix BioTherapeutics Q1 Earnings Preview
Seeking Alpha · 05/12 18:07
Weekly Report: what happened at PLX last week (0504-0508)?
Weekly Report · 05/11 09:39
Weekly Report: what happened at PLX last week (0427-0501)?
Weekly Report · 05/04 09:38
Weekly Report: what happened at PLX last week (0420-0424)?
Weekly Report · 04/27 09:39
More
Webull provides a variety of real-time PLX stock news. You can receive the latest news about Protalix Biother through multiple platforms. This information may help you make smarter investment decisions.
About PLX
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of uncontrolled gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase) - a chemically modified enzyme to treat uncontrolled gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate. Its product includes Elelyso and Elfabrio. Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease.